Interpace Diagnostics Announces New Analyses Showing Positive Impact of PancraGEN™ in the Clinical Management of Pancreatic Cysts

By: via Benzinga
PDI, Inc. (NASDAQ: PDII) subsidiary, Interpace Diagnostics, announced data that were presented in two posters during the American ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.